Pay in 4 interest-free payments of $5.28 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
Counseling and education are equally important, enabling women to understand their condition and make informed decisions about treatment options
If successful, proceed based on your plan tier (Question 3)
The Phase 2 trial enrolled participants with obesity and evaluated multiple dose levels over 48 weeks: 1 mg dose: 8.7% average body weight reduction 4 mg dose (escalated from 2 mg): 17.1% average body weight reduction 8 mg dose (escalated from 2 mg): 22.8% average body weight reduction 12 mg dose (escalated from 2 mg): 24.2% average body weight reduction Placebo: 2.1% average body weight reduction Those Phase 2 numbers were striking enough
Signature Shots B12 Shot The classic energy and wellness boost
Atul Malothra presented findings from the Surmount OSA trial, focusing on the potential of tirzepatide in treating obesity-related Obstructive Sleep Apnea (OSA)
